Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects
China’s leading supplier of congenital heart disease devices made its third filing earlier this month for a Hong Kong IPO Key Takeaways: After taking its Lepu Biopharma unit public in…
RELATED ARTICLES
-
Rebounding Perfect Medical finds beauty safe haven in Hong Kong
1830.HK
- Medical imaging group Rimag sets growth focus with IPO
- Malo Medical pitches IPO to help fill China’s dentistry gap
- HeyTea brings its bubbly brew to Europe. But are its prospects deflating?
-
IFlytek hives off health unit to fund AI medical drive
002230.SHE
- Zeekr steps on IPO accelerator as its prospects run low on fuel
- Lantian takes swipe at IPO, but slow growth may dampen its prospects
Discover hidden China stock gems in our weekly newsletter